On March 31, 2025 Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company (the "Company’"), reported the completion of the safety lead-in of its Phase 2 clinical trial of ENV105 for the treatment of metastatic, castration-resistant prostate cancer (Press release, Kairos Pharma, MAR 31, 2025, View Source [SID1234651703]). The trial, titled, "Phase II study of Apalutamide with Carotuximab (ENV105) in Metastatic, Castration Resistant Prostate Cancer," began with the safety lead-in, which combined apalutamide, a standard of care for prostate cancer, with the Company’s compound ENV105.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The second part of the study, which randomizes patients to receive either apalutamide alone or in combination with ENV105 is ongoing. The Company expects to announce the safety and efficacy data readout from the safety arm of the trial beginning in the first half of 2025.
"This is an important milestone in this trial as it helps to establish the safety and preliminary efficacy of the combination therapy with ENV105, which is essential in order to proceed with the randomized portion of the trial. We are very pleased with the rate of our progress thus far and are grateful to our participating centers for their continued dedication to the trial," said John Yu, M.D., Kairos CEO.
The Company is also validating biomarkers throughout the study to best identify those patients believed to have the most benefit for the combination therapy. In the meantime, the Company continues to enroll patients for the randomization arm of the study at key cancer centers in Los Angeles and Salt Lake City. The trial is supported by Kairos Pharma Ltd. and a grant from the National Cancer Institute (NCI).